GSK Submits Final Study Data on Cervical Cancer Vaccine to FDA

Drug Industry Daily
A A
GlaxoSmithKline (GSK) has given the FDA final data from its Phase III study of Cervarix, an investigational vaccine to prevent cervical cancer and pre-cancerous cervical lesions caused by human papillomavirus (HPV) types 16 and 18.

To View This Article:

Login

Subscribe To Drug Industry Daily